您的购物车当前为空
别名 Temab-A, ABBV-400
Telisotuzumab Adizutecan (ABBV-400) 是一种抗-c-Met抗体-药物偶联物 (ADC),由人源化抗c-Met抗体Telisotuzumab、稳定可裂解的linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane) 和拓扑异构酶1 (topoisomerase1) 抑制剂 (7-MAD-MDCPT) 组成。其ADC的药物-连接体偶联物为TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT。Telisotuzumab Adizutecan 对结直肠癌、胃癌和非小细胞肺癌等晚期癌症实体瘤展示了显著的抗肿瘤活性。
Telisotuzumab Adizutecan (ABBV-400) 是一种抗-c-Met抗体-药物偶联物 (ADC),由人源化抗c-Met抗体Telisotuzumab、稳定可裂解的linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane) 和拓扑异构酶1 (topoisomerase1) 抑制剂 (7-MAD-MDCPT) 组成。其ADC的药物-连接体偶联物为TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT。Telisotuzumab Adizutecan 对结直肠癌、胃癌和非小细胞肺癌等晚期癌症实体瘤展示了显著的抗肿瘤活性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 12,000 | 待询 | |
| 5 mg | 待询 | 待询 |
| 产品描述 | Telisotuzumab Adizutecan (ABBV-400) is an antibody-drug conjugate (ADC) targeting c-Met. It consists of the humanized anti-c-Met antibody Telisotuzumab, a stable cleavable linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane), and a topoisomerase 1 inhibitor (7-MAD-MDCPT). The drug-linker conjugate of the ADC is TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT. Telisotuzumab Adizutecan exhibits significant antitumor activity against advanced solid tumors such as colorectal, gastric, and non-small cell lung cancers. |
| 别名 | Temab-A, ABBV-400 |
| 存储 | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多